Table 3.
The findings of meta-regression analysis.
| Variables | Predictor variable | Heterogeneity accounted for | Residual heterogeneity (I2) | Test of moderator (P-value) |
|---|---|---|---|---|
| SBP | Publication year | 3.99 % | 87.30 % | 0.28 |
| Sample size | 0.0 % | 89.17 % | 0.43 | |
| Dose | 9.61 % | 88.51 % | 0.06 | |
| Trial Duration | 4.80 % | 88.92 % | 0.07 | |
| DBP | Publication year | 0.45 % | 90.29 % | 0.42 |
| Sample size | 0.0 % | 91.68 % | 0.44 | |
| Dose | 0.0 % | 90.92 % | 0.52 | |
| Trial Duration | 0.0 % | 92.02 % | 0.89 | |
| HR | Publication year | 0.0 % | 0.0 % | 0.70 |
| Sample size | 0.0 % | 0.0 % | 0.70 | |
| Dose | 0.0 % | 0.0 % | 0.52 | |
| Trial Duration | 0.0 % | 0.0 % | 0.34 |
(SBP: Systolic Blood pressure, DBP: diastolic blood pressure; HR: heart rate).